Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2007, Pages 869-878

  Hirschowitz, B I ^a   Worthington, J ^a   Mohnen, J ^a   Haber, M ^b  

^a University of Alabama at Birmingham   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHROMOGRANIN; CHROMOGRANIN A; GASTRIN; LANSOPRAZOLE;

ACHLORHYDRIA; ACID HYPERSECRETION; ADULT; ARTICLE; CARCINOID; CELL ACTIVITY; CELL HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENTEROCHROMAFFIN LIKE CELL; FEMALE; GASTRIN BLOOD LEVEL; GASTRINOMA; GASTROINTESTINAL DISEASE; HUMAN; HYPERGASTRINEMIA; MAJOR CLINICAL STUDY; MALE; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; STOMACH BIOPSY; STOMACH CARCINOMA; STOMACH SECRETION; TREATMENT DURATION; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; CHROMOGRANIN A; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENTEROCHROMAFFIN CELLS; ENTEROCHROMAFFIN-LIKE CELLS; FEMALE; GASTRINS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; ZOLLINGER-ELLISON SYNDROME;

EID: 34548354906     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03439.x     Document Type: Article

References (36)

1. Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965 97 : 40C 1C.
2. Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HP, O'Connor DT. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. J Clin Endocrinol Metab 1990 71 : 360 9.
3. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003 348 : 1134 49.
4. Bashir S, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther 2002 16 : 1367 82.
5. Ferrari L, Seregni E, Bajetta E, Martinetti A, Bombardieri E. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res 1999 19 : 3415 27.
6. Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 1999 85 : 1470 83.
7. Lamberts SW, Hofland LJ, Nobels FR. Neuroendocrine tumor markers. Front Neuroendocrinol 2001 22 : 309 39.
8. Nanes MS, O'Connor DT, Marx SJ. Plasma chromogranin-A in primary hyperparathyroidism. J Clin Endocrinol Metab 1989 69 : 950 5.
9. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998 28 : 431 40.
10. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997 82 : 2622 8.
11. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986 314 : 1145 51.
12. Stabile BE, Howard TJ, Passaro E Jr., O'Connor DT. Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg 1990 125 : 451 3.
13. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995 144 : 49 59.
14. Hirschowitz BI, Simmons J, Mohnen J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 2001 15 : 1795 806.
15. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005 3 : 39 48.
16. Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001 15 : 87 103.
17. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006 98 : 4 19.
18. Sanduleanu S, De Bruine A, Stridsberg M, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001 31 : 802 11.
19. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992 51 (Suppl. 1 82 92.
20. Kern SE, Yardley JH, Lazenby AJ, et al. Reversal by antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: a morphometric study. Mod Pathol 1990 3 : 561 6.
21. Larsson H, Carlsson E, Mattsson H, et al. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986 90 : 391 9.
22. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996 20 : 1161 81.
23. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988 41 : 185 200.
24. Bordi C, D'Adda T, Azzoni C, Ferraro G. Classification of gastric endocrine cells at the light and electron microscopical levels. Microsc Res Tech 2000 48 : 258 71.
25. Dayal Y Hyperplastic proliferations of the ECL cells. Yale J Biol Med 1992 65 : 805 25 discussion 827-9.
26. Pesce C, Rossi R, Lenti E, Tanzi R. G-cell density in the antral mucosa: a feasibility study. Histopathology 1997 30 : 315 8.
27. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005 128 : 1717 51.
28. Borch K, Renvall H, Liedberg G, Andersen BN. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986 21 : 357 63.
29. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997 32 : 198 202.
30. Ruszniewski P, Podevin P, Cadiot G, et al. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 1993 8 : 295 304.
31. Kitano M, Norlen P, Hakanson R. Gastric submucosal microdialysis: a method to study gastrin- and food-evoked mobilization of ECL-cell histamine in conscious rats. Regul Pept 2000 86 : 113 23.
32. Hirschowitz BI, Danilewitz M, Molina E. Inhibition of basal acid, chloride, and pepsin secretion in duodenal ulcer by graded doses of ranitidine and atropine with studies of pharmacokinetics of ranitidine. Gastroenterology 1982 82 : 1314 26.
33. Watkinson A, Dockray GJ. Functional control of chromogranin A and B concentrations in the body of the rat stomach. Regul Pept 1992 40 : 51 61.
34. Hirschowitz BI. Clinical aspects of ECL-cell abnormalities. Yale J Biol Med 1998 71 : 303 10.
35. Korman MG, Soveny C, Hansky J. Paradoxical effect of secretin on serum immunoreactive gastrin in the Zollinger-Ellison syndrome. Digestion 1973 8 : 407 16.
36. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992 102 : 1409 18.